The hepatitis C revolution part 1: antiviral treatment options

@article{Thiagarajan2015TheHC,
  title={The hepatitis C revolution part 1: antiviral treatment options},
  author={P. Thiagarajan and S. Ryder},
  journal={Current Opinion in Infectious Diseases},
  year={2015},
  volume={28},
  pages={563–571}
}
  • P. Thiagarajan, S. Ryder
  • Published 2015
  • Medicine
  • Current Opinion in Infectious Diseases
  • Purpose of review The rapid evolution in the therapeutic landscape of hepatitis C presents a minefield to clinicians seeking to optimize therapy for their patients. Efficacy, evidence-base, side-effects, and drug combinations must be tailored to individual patients, taking into account comorbidities, degree of fibrosis, evidence of hepatic decompensation, and life expectancy. The review article aims to discuss novel hepatitis C virus (HCV) treatments with an overview of recent breakthrough… CONTINUE READING
    12 Citations
    Evolution of matrinic ethanol derivatives as anti-HCV agents from matrine skeleton.
    • 8
    Hepatitis C core antigen highly correlated to HCV RNA
    • 5
    Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation
    • 44
    • PDF

    References

    SHOWING 1-10 OF 56 REFERENCES
    Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
    • 26
    • PDF
    Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    • D. Wyles
    • Medicine
    • The Journal of infectious diseases
    • 2013
    • 82
    • PDF
    Expert opinion on the treatment of patients with chronic hepatitis C
    • 218
    NS5A inhibitors in the treatment of hepatitis C.
    • 157
    Novel therapies for hepatitis C — one pill fits all?
    • 178